Manager TitleAgeSince
Director of Finance/CFO 71 31/03/2017
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 64 31/12/2017
Director/Board Member 71 31/12/2017
Director/Board Member 52 20/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-31.03%-40.43% - - 64.67K
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -4.92%-1.93%+57.77%+191.52% 31.33B
Weighted average by Cap. -1.93%-1.50%+53.73%+151.51%
Logo Asarina Pharma AB
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
Employees
6
  1. Stock Market
  2. Stocks
  3. ASAP Stock